منابع مشابه
MicroRNAs in Myeloid Hematological Malignancies
MicroRNAs are 19-24 nucleotides noncoding RNAs which silence modulate the expression of target genes by binding to the messenger RNAs. Myeloid malignancies include a broad spectrum of acute and chronic disorders originating from from the clonal transformation of a hematopoietic stem cell. Specific genetic abnormalities may define myeloid malignancies, such as translocation t(9;22) that represen...
متن کاملdel(13q) in myeloid malignancies
Note Chromosomal deletions are among the most common genetic events observed in hematologic malignancies; loss of genetic materiel is regarded as a hallmark of putative tumor suppressor gene localization. Deletions 13q occurs in lymphoid neoplasias: see del(13q) in non-Hodgkin's lymphoma and del(13q) in chronic lymphoproliferative diseases. In myeloid disorders, the most frequently reported del...
متن کاملPathogenic microRNA’s in myeloid malignancies
Recent studies have significantly improved our understanding of the role microRNAs (miRNAs) play in regulating normal hematopoiesis. miRNAs are critical for maintaining hematopoietic stem cell function and the development of mature progeny. Thus, perhaps it is not surprising that miRNAs serve as oncogenes and tumor suppressors in hematologic malignancies arising from hematopoietic stem and prog...
متن کاملTGFα expression in myeloid malignancies
BACKGROUND Transforming growth factor α (TGFα) is a peptide growth factor known to be expressed in normal haemopoiesis. It is also expressed in a range of epithelial neoplasms but has not been assessed in haemopoietic malignancies. We have performed an immunohistochemical evaluation of TGFα in acute and chronic myeloid malignancies. METHODS TGFα expression was semiquantitatively assessed in 6...
متن کاملTherapy-Related Myeloid Malignancies in
Therapy related myeloid malignancies are an increasingly recognized treat complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have been raised regarding the immunomodulatory agent lenal antimyeloma agents in the context of therapy related myeloid malignanci...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Atlas of Genetics and Cytogenetics in Oncology and Haematology
سال: 2011
ISSN: 1768-3262
DOI: 10.4267/2042/44500